Dear Editor,

I have read with interest a recent report by Kumar et al. \[[@B1]\] on the putative role of interleukin-6 (IL-6) in ischemic stroke. In their report, the authors refute an association of 2 promoter variants on the phenotype under study based on earlier case-control investigations. Data from this article, however, warrant a reappraisal of existing findings.

On one hand, numerous investigations were not retrieved. A quick search using the same databases as employed by the authors unveiled additional studies both for −572G/C \[[@B2],[@B3]\] and for −174G/C \[[@B4],[@B5],[@B6]\] and around 10,000 additional genotypes that had been available at the time of the August 30, 2014, data freeze. I am not even counting the genome-wide association studies that were published from 2007 onward \[[@B7]\]. On the other hand, the results cited in the article appear to have been muddled. Thus, a study by Flex et al. \[[@B8]\] refers to an entirely different phenotype of peripheral artery occlusive disease (only 22 patients actually also had a history of stroke). Assuming that the authors had intended to refer to another study by the same author \[[@B9]\], we face the obvious overlap of cases and controls with a further investigation \[[@B10]\]. Similarly, overlap of cases and controls was ignored for the studies by Revilla et al. \[[@B11]\] and Chamorro et al. \[[@B12]\]. The number of cases and controls pooled is thus inflated. Another issue that has been overlooked is the sharp discrepancy in −174C allele frequencies in the studies by Yamada et al. \[[@B13]\] and Tong et al. \[[@B14]\]. No alleles have so far been identified with frequencies ranging from 0.22 to 0.76 in non-isolated Asian (or Caucasian) populations. The only reasonable explanation for this discordant observation is a muddling of major and minor alleles at some point, and therefore, the outlier study should have been dropped from the meta-analysis. On the whole, the present quantitative review is best reconducted to eliminate the above sources of bias and to provide an accurate estimate of IL-6 impact on the susceptibilty to ischemic stroke.
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